Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:RVV
DateTimeSourceHeadlineSymbolCompany
19/04/202200:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
12/04/202222:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
30/03/202200:57InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
14/02/202222:53InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
18/01/202201:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsCSE:RVVRevive Therapeutics Ltd
08/01/202200:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
18/08/202120:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerCSE:RVVRevive Therapeutics Ltd
12/08/202123:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationCSE:RVVRevive Therapeutics Ltd
10/08/202122:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineCSE:RVVRevive Therapeutics Ltd
28/06/202122:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketCSE:RVVRevive Therapeutics Ltd
08/06/202123:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaCSE:RVVRevive Therapeutics Ltd
17/05/202123:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripCSE:RVVRevive Therapeutics Ltd
03/05/202123:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19CSE:RVVRevive Therapeutics Ltd
22/04/202122:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contCSE:RVVRevive Therapeutics Ltd
25/03/202100:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
12/02/202100:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramCSE:RVVRevive Therapeutics Ltd
28/01/202100:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentCSE:RVVRevive Therapeutics Ltd
19/01/202101:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesCSE:RVVRevive Therapeutics Ltd
01/01/202100:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyCSE:RVVRevive Therapeutics Ltd
23/12/202003:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramCSE:RVVRevive Therapeutics Ltd
31/10/202004:39InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
31/07/202023:46InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
23/04/202023:47InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical TrialCSE:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:CSE:RVV